Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, COVID-19, Communication Research, Health Behavior, Respiratory Viral Infection
Interventions: Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3, Science communication curriculum Cohort 4; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan

Conditions: Healthy
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 49 Years
Enrollment: 63,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 77
States / cities: Alameda, California • Antioch, California • Clovis, California + 49 more

Conditions: Influenza, Human, Orthomyxoviridae Infections, RNA Virus Infections, Virus Disease, Respiratory Tract Infections, Respiratory Tract Disease, Vaccines, Physiological Effects of Drugs
Interventions: R/R - Autodialers, R/R - Texting, R/R - mailed postcard; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months to 17 Years
Enrollment: 70,190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein); Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza
Interventions: Ca/04/2009/H1N1 Vero Grown Challenge Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Fluzone, Flucelvax, Fluzone High-Dose, Fluad; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: Influenza A/H9N2 vaccine, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 34 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 36
States / cities: Los Angeles, California • Oakland, California • Aurora, Colorado + 30 more

Conditions: Influenza
Interventions: Baloxavir Marboxil, Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Harrisburg, Arkansas • Jonesboro, Arkansas + 22 more

Conditions: Influenza
Interventions: Panblok, rHA adjuvant; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Mobile, Alabama • DeLand, Florida • Savannah, Georgia + 6 more

Conditions: Influenza
Interventions: Influenza virus vaccine (CAIV-T); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Months to 18 Years
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Bifidobacterium lactis HN019, Placebo; Dietary Supplement
Lead sponsor: Fonterra Research Centre; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 426 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Coral Gables, Florida • Rochester, Michigan

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
Interventions: Quadrivalent VLP Vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 10,160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more

Conditions: HIV Infection
Interventions: Fluzone®; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza, Infant, Premature
Interventions: Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 6 Months to 17 Months
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Miami, Florida • Buffalo, New York • Rochester, New York + 2 more

Conditions: MAJOR DEPRESSIVE DISORDER
Interventions: INFLUENZA VACCINE, NaCl-saline placebo; Biological · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Influenza
Interventions: Seasonal Influenza DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more

Conditions: Influenza Virus Infection Transmission in Humans
Interventions: Observational Study of influenza aerosol shedding -- No Intervention; Other
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 10 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Influenza
Interventions: A/Shanghai/02/2013 (H7N9) MIV, VRC-FLUDNA071-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: text message; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Behavior, Health, Flu, Flu Vaccination
Interventions: Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback, High risk bidirectional pre-visit text messaging; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 26,248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Virus Diseases
Interventions: GSK1325756 (Danirixin), Placebo To Match GSK1325756, Oseltamivir Phosphate, Placebo To Match Oseltamivir Phosphate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more

Conditions: Influenza
Interventions: Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Edison, New Jersey • Austin, Texas

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Search by objective public record fields.

Dime La VerDAD: Verify, Debunk, and Disseminate

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Centralized Reminder Recall - Flu RCT2

Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine

Influenza A 2009 H1N1 Challenge Study in Healthy Adults

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older

Study of a Flu Vaccine in Children

Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals

Influenza Vaccine in Premature Infants

Influenza Challenge in Mood Disorders

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Pilot Text Message for Influenza Vaccination

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects